Table 2.
Demographics and baseline characteristics
| Characteristic | BE VIVID (n = 567) |
BE READY (n = 435) |
Pooled (n = 1002) |
|---|---|---|---|
| Age, years, mean (SD) | 46.1 (13.9) | 44.3 (12.9) | 45.3 (13.5) |
| Gender, n (%) | |||
| Male | 406 (71.6%) | 313 (72.0%) | 719 (71.8%) |
| Female | 161 (28.4%) | 122 (28.0%) | 283 (28.2%) |
| Race, n (%) | |||
| White | 420 (74.1%) | 403 (92.6%) | 823 (82.1%) |
| Black or African American | 12 (2.1%) | 6 (1.4%) | 18 (1.8%) |
| Asian | 127 (22.4%) | 18 (4.1%) | 145 (14.5%) |
| American Indian or Alaska native | 2 (0.4%) | 0 (0.0%) | 2 (0.2%) |
| Native Hawaiian or other Pacific islander | 0 (0.0%) | 2 (0.5%) | 2 (0.2%) |
| Other or mixed | 6 (1.1%) | 6 (1.4%) | 12 (1.2%) |
| Country, n (%) | |||
| USA | 116 (20.5%) | 85 (19.5%) | 201 (20.1%) |
| Canada | 61 (10.8%) | 89 (20.5%) | 150 (15.0%) |
| Belgium | 6 (1.1%) | 0 (0.0%) | 6 (0.6%) |
| Germany | 62 (10.9%) | 38 (8.7%) | 100 (10.0%) |
| Italy | 4 (0.7%) | 0 (0.0%) | 4 (0.4%) |
| UK | 7 (1.2%) | 6 (1.4%) | 13 (1.3%) |
| Hungary | 27 (4.8%) | 31 (7.1%) | 58 (5.8%) |
| Poland | 143 (25.2%) | 150 (34.5%) | 293 (29.2%) |
| Russian Federation | 19 (3.4%) | 19 (4.4%) | 38 (3.8%) |
| Australia | 14 (2.5%) | 10 (2.3%) | 24 (2.4%) |
| Japan | 108 (19.0%) | 0 (0.0%) | 108 (10.8%) |
| Korea | 0 (0.0%) | 7 (1.6%) | 7 (0.7%) |
| Duration of disease, years, mean (SD) | 17.1 (12.0) | 19.5 (13.1) | 18.1 (12.6) |
| Baseline PASI, n (%) | |||
| PASI < 20 | 326 (57.5%) | 274 (63.0%) | 600 (59.9%) |
| PASI ≥ 20 | 240 (42.3%) | 161 (37.0%) | 401 (40.0%) |
| Missing | 1 (0.2%) | 0 (0.0%) | 1 (0.1%) |
| BSA affected by psoriasis, %, mean (SD) | 28.2 (16.9) | 24.5 (15.4) | 26.6 (16.3) |
| mNAPSI total score, mean (SD) | 12.8 (18.8) | 12.3 (19.4) | 12.6 (19.0) |
| PGADA for arthritis VAS Score, mean (SD) | 20.1 (27.5) | 24.7 (27.7) | 22.1 (27.6) |
| Nail involvement, n (%) | |||
| Yes | 354 (62.4%) | 260 (59.8%) | 614 (61.3%) |
| No | 213 (37.6%) | 175 (40.2%) | 388 (38.7%) |
| mNAPSI total score for patients with nail involvement | |||
| n | 354 | 260 | 614 |
| Mean (SD) | 20.3 (20.2) | 20.6 (21.4) | 20.4 (20.7) |
| Scalp involvement, n (%) | |||
| Yes | 530 (93.5%) | 397 (91.3%) | 927 (92.5%) |
| No | 37 (6.5%) | 38 (8.7%) | 75 (7.5%) |
| Palmoplantar involvement, n (%) | |||
| Yes | 227 (40.0%) | 161 (37.0%) | 388 (38.7%) |
| No | 340 (60.0%) | 274 (63.0%) | 614 (61.3%) |
BSA body surface area affected, mNAPSI modified Nail Psoriasis Severity Index, PASI Psoriasis Area and Severity Index, PGADA Patient Global Assessment of Disease Activity, SD standard deviation, VAS visual analogue scale